

Immunization schedules in the Americas: looking to the future

Edwin J. Asturias, MD

Associate Professor of Pediatric Infectious Diseases
and Epidemiology, Center for Global Health

XI International Symposium for Latin American experts

Organized by: Fondation Mérieux and the Latin American Society
for Pediatric Infectious Diseases (SLIPE)

Definition of immunization schedule

*“An immunization schedule is a schematic of the **ideal timing** of administration of one or more vaccines, based on the **best opportunity to provide protection and minimize risk** in the prevention of vaccine preventable diseases.”*

Edwin J. Asturias

- Individual-based schedules
- Community-protection based schedule

Why are schedules important?

- **Programmatic:** framework for delivery of vaccines to target population
- **Evaluation of coverage**
- **Research and development:** Parameters for vaccine studies (harmonization with existing vaccine schedules...)
- **Public guidance and confidence**

Immunization Schedules in the United States and Great Britain -1967-68

TABLE 1. Recommended schedules for routine immunization

United States*					England and Wales†					
Age	DTP	OPV	M	SP	Age	DTP	OPV	M	SP	BCG
2-3 months	X	X			3-6 months	X	X			
3-4 months	X				5-8 months	X	X			
4-5 months	X	X			9-14 months	X	X			
12-18 months	X	X	X		12-24 months			X	X	
12-24 months				X	School entry (3-6 years)	Td	X		X	
School entry (3-6 years)	X	X		X	10-13 years					X
Every 10 years	Td			X‡	School leaving	Td	X		X	

DTP, Diphtheria-tetanus-pertussis vaccine; OPV, oral poliovaccine; M, measles vaccine; SP, smallpox vaccine; Td, tetanus-diphtheria toxoid, adult type.

* Adopted from United States Public Health Service (1967): *Immunization Against Disease 1966-67* (National Communicable Disease Center publication).

† Adopted from Ministry of Health (1968a,b).

‡ For high risk groups, i.e. health personnel and overseas travel—every 3 years.

Karzon, DT. *Postgrad Med J* 45; 147: 1969

Childhood (0-18 months) Immunization schedules in the USA and UK 2018

United States 2018


United Kingdom 2018

Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos	18 mos
Hepatitis B ¹ (HepB)	1 st dose	← 2 nd dose →					← 3 rd dose →		
Rotavirus ² (RV) RV1 (2-dose series); RV5 (3-dose series)			1 st dose	2 nd dose	See footnote 2				
Diphtheria, tetanus, & acellular pertussis ¹ (DTaP: <7 yrs)			1 st dose	2 nd dose	3 rd dose			← 4 th dose →	
Haemophilus influenzae type b ¹ (Hib)			1 st dose	2 nd dose	See footnote 4		← 3 rd or 4 th dose → See footnote 4		
Pneumococcal conjugate ² (PCV13)			1 st dose	2 nd dose	3 rd dose		← 4 th dose →		
Inactivated poliovirus ¹ (IPV: <18 yrs)			1 st dose	2 nd dose			← 3 rd dose →		
Influenza ¹ (IV)							Annual vaccination (IV) 1 st		
Measles, mumps, rubella ² (MMR)					See footnote 8		← 1 st dose →		
Varicella ² (VAR)							← 1 st dose →		
Hepatitis A ^{1,3} (HepA)							← 2-dose series, See footnote 2		

Age due	Vaccine given	How it is given ¹
Eight weeks old (2m)	Diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b (Hib) (DTaP/IPV/Hib) Pneumococcal conjugate vaccine (PCV) Meningococcal B (MenB) ² Rotavirus	One injection One injection One injection One oral applica
Twelve weeks old ³ (3m)	Diphtheria, tetanus, pertussis, polio and Hib (DTaP/IPV/Hib) Rotavirus	One injection One oral applica
Sixteen weeks old (4m)	Diphtheria, tetanus, pertussis, polio and Hib (DTaP/IPV/Hib) Meningococcal B (MenB) ² Pneumococcal conjugate vaccine (PCV)	One injection One injection One injection
One year old (i.e. within a month of the first birthday) ⁴ (12m)	Hib/MenC booster Pneumococcal conjugate vaccine (PCV) booster Measles, mumps and rubella (MMR) Meningococcal B (MenB) booster ²	One injection One injection One injection One injection

Global vaccine coverage estimates 1980-2016

DPT-1 and DPT-3 by completion





OPS - OMS
PAHO - WHO

The Impact of Vaccines in the Americas

1980

2015

All Vaccine Preventable Diseases

392,178



31,254

Measles **257,826**



613*

Rubella **158,638**



3

Pertussis **123,138**



11,432


Diphtheria **5,834**




0

http://ais.paho.org/phil/viz/im_vaccinepreventablediseases.asp


Elements used to design an optimal schedule for the primary series in infants








Seroconversion rates by age in developing countries after measles immunization (1 dose)




Global coverage and schedules of measles containing vaccines – June 2016




	<50%	(4 countries or 2%)
	50–79%	(38 countries or 20%)
	80–89%	(33 countries or 17%)
	90–94%	(40 countries or 21%)
	≥95%	(79 countries or 40%)

Measles case distribution by month and WHO Region (2014-2018)




Notes: Based on data received 2018-09 - Data Source: IVB Database - This is surveillance data, hence for the last month(s), the data may be incomplete.

Coverage of MMR1 and MMR2 vaccines in countries in the Americas Region 2017




MMR-dose 1

MMR-dose 2




Proportion of infants of vaccinated and naturally immune women still immune as a function of time to loss of immunity


Belgium




Canada




Measles age-specific incidence by Region 2011-2016




Measles Cases (%), by Age Group, 2011-2016



GMC responses to diphtheria and tetanus in children receiving 3 doses of DTwP-IPV by interval




Meta-analysis of Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses







Hib invasive disease incidence in UK 1990-2015




Countries having introduced Hib vaccine in 1997 and 2014


Percent of children by schedule globally



1997



Modelling the effects of booster dose Hib schedules for public health immunization




Assuming
90% coverage

Primary series only

Primary series +
booster 1 year

Primary series +
booster 2-4 years

Current DPT-Hib Series Schedules in the Region of the Americas 2018




Primary series


-  6-10-14 weeks
-  2-4-6 months
-  2-3-4(5) months
-  3-5-12 months

Pneumococcal Serotype-Specific Antibody GMCs Measured at 4 different Time Points (95% CI) in 4 different schedules in Netherlands

B 1 Month after primary series



Pneumococcal Serotype-Specific Antibody GMCs Measured at 4 different Time Points (95% CI) in 4 different schedules in Netherlands





Pneumococcal vaccine introduction as of 2015 – 190,000 deaths averted





Outcome	Vaccine Type (VT) Disease
Immunogenicity	<u>Antibody concentration (GMC):</u> - 3 primary doses more immunogenic than 2 primary doses - 2+1 more immunogenic after 3 rd dose <u>% Responders:</u> Schedules showed similar impact except for 6A, 6B and 23F
NP Carriage	Schedules showed similar impact
IPD	VT: Both schedules showed similar impact ; Limited 3+0 data ST1: Clear evidence of 2+1 impact; evidence of 3+0 impact but limited data
Overall	Both schedules are effective in reducing VT Carriage and Disease

Current Rotavirus and PCV Schedules in the Region of the Americas 2018




Current DPT-Hib Series Schedules in the Region of the Americas 2018




Countries with recommended for immunization of pregnant women 2018


TT/Td vaccine coverage 2016



Influenza vaccine recommended 2018




Integrating Maternal and Infant Schedules




Vaccine schedules and conjugate (Hib) vaccines in special populations (HIV, PTB)

Figure 2: Global burden of preterm birth in 2010



Source: Blencowe et al National, Note: rates by country are available on the accompanying wall chart. Not applicable for non-WHO Member States


Pneumococcal (PCV13) IgG GMCs after primary vaccination for each serotype and group in premature infants in the UK



Vaccination schedules for Population Immunity (Community Protection)

- **HepA vaccine: 2 vs. 1 dose**
- **PCV: UK 1+1 schedule?**
- **IPV: 1-2 doses – best timing and issues with silent transmission (more tomorrow)**


Trend of Hepatitis A incidence rates and cases of hepatic failure due to HAV in Argentina pre and post 1 dose HAV program



Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants


Prof David Goldblatt, MBChB, Jo Southern, PhD, Nick J Andrews, PhD, Polly Burbidge, BSc, Jo Partington, BSc, Lucy Roalfe, BSc, Marta Valente Pinto, MD, Vasilli Thalasselis, Emma Plested, Hayley Richardson, BSc, Matthew D Snape, MBChB, Prof Elizabeth Miller, FRCPath

% with serotype specific immunoglobulin G concentrations of 0.35 µg/mL or higher





Trends in vaccine hesitancy and the importance of safety in the Americas Region

“Overall, I think vaccines are safe...”



Center for Global Health
 COLORADO SCHOOL OF PUBLIC HEALTH

Vaccine preferences by antigen and safety in different populations Guatemala




Data: Desiree Pastor, PAHO


Dela Fuente Paediatr Child Health. 2016 Mar;21(2):e15-6




Number of Vaccines/Antigens Introduced Nationwide in Immunization Schedules - 2000 compared to date



Selected antigens are :
 Diphtheria, Tetanus, Pertussis, Measles, Polio - universal use
 Hepatitis B,
 Haemophilus Influenza type B,
 Pneumococcal conjugate
 Rotavirus
 Rubella



2,700 5,400 km



Data Source: WHO/IVB Database, as at 20 July 2015



Map production: Immunization Vaccines and Biologicals, (IVB), World Health Organization

Date of slide: 20 July 2015

The boundaries and names shown, and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.
 © WHO 2015. All rights reserved.



NITAG strengthening in the Americas 2011-2017 and country decision



- NITAG (No further data available or neither terms of reference nor legislative basis)
- NITAG meets 1 to 5 WHO criteria
- NITAG meets all 6 basic WHO criteria
- Non applicable
- None

Comparison of challenges for immunization schedules in HIC and Latin America

Issue	Latin America	Europe	USA
Alignment with best immunogenicity	++	+++	++
Booster doses	+	+++	+++
Crowding of injections	+ / +++	+++	+++
Vaccine hesitancy/spacers	+ / -	++	+++
Maternal immunization	+ / -	++	++
Programmatic flexibility	+	++	+ / -

Summary

- **Immunization schedules in the Americas have fostered development and introduction of life-saving vaccines**
- **Boosters \geq 12 months** crucial for long term and indirect protection
- **Primary series could be modified**
 - Ages for best immunological fit and delivery
 - **2 doses in the first year** probably sufficient
- Schedules will need to address **safety and crowding** for upcoming vaccines and confidence